Betrixaban

• CAT Number: I003189
• CAS Number: 330942-05-7
• Molecular Formula: C23H22ClN5O3
• Molecular Weight: 451.9
• Purity: ≥95%
• Synonyms: N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
• Target: Factor Xa
• Solubility: DMSO: ≤ 22 mg/mL
• Storage: Store at +4C
• IC50: 1.2 nM
• InChIKey: XHOLNRLADUSQLD-UHFFFAOYSA-N
• SMILES: ClC1=CC=C(NC(C2=CC(OC)=CC=C2NC(C3=CC=C(C(N(C)C)=N)C=C3)=O)=O)N=C1

Betrixaban (CAT: I003189) is an oral anticoagulant belonging to the class of direct factor Xa inhibitors. It exhibits potent antithrombotic activity by selectively inhibiting the activity of factor Xa, a crucial enzyme involved in the blood coagulation cascade. Betrixaban is primarily used for the prevention of venous thromboembolism (VTE) in adult patients who are at risk due to conditions such as atrial fibrillation or extended hospitalization. It is also employed for the prophylaxis of VTE in patients undergoing hip or knee replacement surgery. Betrixaban’s mechanism of action and selectivity make it an effective option in preventing clot formation and reducing the risk of thromboembolic events.

Reference

1:The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Gibson CM, Halaby R, Korjian S, Daaboul Y, Arbetter DF, Yee MK, Goldhaber SZ, Hull R, Hernandez AF, Lu SP, Bandman O, Leeds JM, Gold A, Harrington RA, Cohen AT; APEX Investigators..Am Heart J. 2017 Mar;185:93-100. doi: 10.1016/j.ahj.2016.12.004. Epub 2016 Dec 18. PMID: 28267480
2:Is There a Role for Betrixaban to Prevent Stroke in Medically Ill Patients? Quinlan DJ, Eikelboom JW, Hart RG.Circulation. 2017 Feb 14;135(7):656-658. doi: 10.1161/CIRCULATIONAHA.116.026170. No abstract available. PMID: 28193799
3:Betrixaban in Acutely Ill Medical Patients. Cave B, Hough A, Rosenstein R.N Engl J Med. 2016 Dec 15;375(24):e50. No abstract available. PMID: 28032973
4:Betrixaban in Acutely Ill Medical Patients. Kakkos SK, Nikolakopoulos K, Tsolakis IA.N Engl J Med. 2016 Dec 15;375(24):e50. No abstract available. PMID: 28032972
5:Betrixaban in Acutely Ill Medical Patients. Patil R, Ghosh K, Shetty S.N Engl J Med. 2016 Dec 15;375(24):e50. doi: 10.1056/NEJMc1613217. No abstract available. PMID: 27974030
6:Betrixaban in Acutely Ill Medical Patients. Cohen AT, Harrington RA, Gibson CM.N Engl J Med. 2016 Dec 15;375(24):e50. doi: 10.1056/NEJMc1613217. No abstract available. PMID: 27974029 Free Article
7:Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Gibson CM, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT; APEX Investigators..Circulation. 2017 Feb 14;135(7):648-655. doi: 10.1161/CIRCULATIONAHA.116.025427. Epub 2016 Nov 14. PMID: 27881569
8:[Betrixaban reduces tromboembolic events]. Schinzel H.Dtsch Med Wochenschr. 2016 Oct;141(22):1598. Epub 2016 Nov 4. German. No abstract available. PMID: 27824409
9:Betrixaban – the next direct factor Xa inhibitor? Thoenes M, Minguet J, Bramlage K, Bramlage P, Ferrero C.Expert Rev Hematol. 2016 Dec;9(12):1111-1117. Epub 2016 Nov 17. Review. PMID: 27809616
10:Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators..N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27. PMID: 27232649 Free Article